Tarsus Pharmaceuticals, Inc.

Biotechnology • Healthcare • Irvine, CA, United States • TARS (NMS)

949 409 1801 15440 Laguna Canyon Road, Irvine, CA 92618, United States

Quarter: Q2 2025 Reported: June 18, 2025 Sentiment: Positive

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction. In addition, the company develops lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Analysis Summary

Tarsus Pharmaceuticals, Inc. held its Annual Meeting of Stockholders on June 12, 2025, where key corporate governance matters were addressed and approved. The meeting achieved a strong quorum with 34,851,820 shares, representing approximately 82.9% of the 42,007,037 outstanding common shares entitled to vote.

Detailed Financial Performance Breakdown: The provided document is a Form 8-K reporting the results of an Annual Meeting of Stockholders. It does not contain any financial performance data such as revenue, net income, earnings per share, or any related growth rates or guidance. Therefore, a detailed financial performance breakdown cannot be provided from this transcript.

Strategic Initiatives and Business Segment Analysis: This 8-K filing is solely focused on the outcomes of the Annual Meeting of Stockholders and does not contain information regarding strategic initiatives, business segment performance, or operational updates. Therefore, no analysis can be provided in this section based on the provided transcript.

Management Commentary and Forward Guidance: The transcript is a factual report of voting results and does not include management commentary or forward guidance on financial performance or future strategic plans.

Competitive Positioning and Market Trends: This document does not provide any information related to Tarsus Pharmaceuticals' competitive positioning, market trends, or industry-specific analysis.

Risk Factors and Concerns Raised: The filing itself does not explicitly raise specific risk factors or concerns beyond the inherent risks associated with corporate governance. All proposals passed with significant majorities, indicating a lack of major stockholder dissent on the matters presented.

Analyst Q&A Highlights: The provided text is a Form 8-K filing detailing stockholder meeting results, not an earnings call transcript. As such, there was no analyst Q&A session.

Summary of Voting Results:
1. Election of Class II Directors: Dr. Bobak Azamian and Dr. Katherine Goodrich were elected to serve until the 2028 annual meeting. Dr. Goodrich received 26,837,786 'For' votes, and Dr. Azamian received 20,770,139 'For' votes.
2. Advisory Vote on Named Executive Officer Compensation: Stockholders overwhelmingly approved the compensation, with 27,132,839 'For' votes against 416,845 'Against' votes, representing approximately 98.5% approval of votes cast.
3. Advisory Vote on Frequency of Executive Compensation Vote: Stockholders voted to conduct future advisory votes on executive compensation annually ('Every 1 Year') with 26,916,300 votes, significantly outweighing the 'Every 2 Years' (3,376) and 'Every 3 Years' (637,239) options.
4. Ratification of Independent Registered Public Accounting Firm: The appointment of Ernst & Young LLP for fiscal year 2025 was ratified with 34,718,262 'For' votes, representing approximately 99.6% approval of votes cast.

Overall, the meeting demonstrated strong stockholder support for the company's current board and executive compensation practices, as well as its choice of auditor. The preference for annual executive compensation votes indicates a desire for regular oversight and engagement from stockholders.

Key Highlights

• All four proposals at the Annual Meeting of Stockholders were approved with strong majorities.
• Dr. Bobak Azamian and Dr. Katherine Goodrich were re-elected as Class II directors until 2028.
• Named executive officer compensation was approved on an advisory basis with approximately 98.5% of votes cast.
• Stockholders advised for future executive compensation votes to be held annually.
• Ernst & Young LLP was ratified as the independent registered public accounting firm for 2025 with approximately 99.6% approval.
• A high quorum of 34,851,820 shares, representing 82.9% of outstanding shares, was achieved.

Financial Metrics

eps

YoY: Not reported in this filing

revenue

N/A

YoY: Not reported in this filing

guidance

net income

N/A

YoY: Not reported in this filing

Positive Signals

• High stockholder participation with a quorum of 82.9%.
• Overwhelming approval for the election of Class II directors.
• Strong advisory approval for named executive officer compensation (98.5% of votes cast).
• Ratification of Ernst & Young LLP as auditors with near-unanimous support (99.6% of votes cast).
• Stockholders' clear preference for annual advisory votes on executive compensation, indicating active engagement.

Risks & Concerns

— The provided 8-K filing focuses solely on the results of the Annual Meeting of Stockholders and does not discuss specific operational, financial, or market-related risk factors.
— Potential for future stockholder dissent on executive compensation, despite current approval, given the preference for annual votes.
— Reliance on key directors and management, whose election was a primary focus of the meeting.
— General corporate governance risks inherent in any public company.